Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy

BMC Medical Research Methodology

Volumn 12, Issue , 2012, Pages

  Gerhard, Tobias ^a,b   Delaney, Joseph A C ^c,d,e   Cooper Dehoff, Rhonda M ^c,d   Shuster, Jonathan ^d   Brumback, Babette A ^d,e   Johnson, Julie A ^c,d   Pepine, Carl J ^d   Winterstein, Almut G ^c,d,e  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

Author keywords

Blood pressure; Hypertension; Marginal structural models; Time dependent confounding

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYDROCHLOROTHIAZIDE; INDOLE DERIVATIVE; TRANDOLAPRIL; VERAPAMIL;

AGED; ARTICLE; AUDIOVISUAL EQUIPMENT; BLOOD PRESSURE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG COMBINATION; DRUG EFFECT; EPIDEMIOLOGY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CONFOUNDING FACTORS (EPIDEMIOLOGY); CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; INDOLES; MALE; MIDDLE AGED; MODELS, STRUCTURAL; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TREATMENT OUTCOME; VERAPAMIL;

MLCS; MLOWN;

EID: 84864528094     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/1471-2288-12-119     Document Type: Article

References (35)

1. Major clinical trials of hypertension: what should be done next? Major clinical trials of hypertension: what should be done next? Hypertension 2005 46 1 6 15911739
2. Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study. Boger-Megiddo I, Heckbert SR, Weiss NS, McKnight B, Furberg CD, Wiggins KL, Delaney JA, Siscovick DS, Larson EB, Lemaitre RN, et al. BMJ 2010 340 103 10.1136/bmj.c103
3. Effects of intensive blood-pressure control in type 2 diabetes mellitus. Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, et al. N Engl J Med 2010 362 1575 1585 20228401
4. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, N Engl J Med 2008 359 2417 2428 10.1056/NEJMoa0806182 19052124
5. Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus. Timbie JW, Hayward RA, Vijan S, Arch Intern Med 2010 170 1037 1044 20585069
6. When clinical practice guidelines meet the black box. Avins AL, Arch Intern Med 2010 170 1013 1014 20585064
7. Marginal structural models and causal inference in epidemiology. Robins JM, Hernan MA, Brumback B, Epidemiology 2000 11 550 560 10.1097/00001648- 200009000-00011 10955408 (Pubitemid 30660034)
8. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F, Lancet 2002 359 1173 1177 10.1016/S0140-6736(02)08213-2 11955534 (Pubitemid 34304256)
9. Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study. Cook NR, Cole SR, Hennekens CH, Am J Epidemiol 2002 155 1045 1053 10.1093/aje/155.11.1045 12034583 (Pubitemid 34587488)
10. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Hernan MA, Brumback B, Robins JM, Epidemiology 2000 11 561 570 10.1097/00001648-200009000-00012 10955409 (Pubitemid 30660035)
11. Traditional versus marginal structural models to estimate the effectiveness of beta-blocker use on mortality after myocardial infarction. Delaney JA, Daskalopoulou SS, Suissa S, Pharmacoepidemiol Drug Saf 2009 18 1 6 10.1002/pds.1676 18949804
12. Estimating antihypertensive effects of combination therapy in an observational study using marginal structural models. Sugihara M, Kushiro T, Saito I, Matsushita Y, Hiramatsu K, Biom J 2009 51 789 800 10.1002/bimj. 200900025 19827055
13. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. Pepine CJ, Handberg-Thurmond E, Marks RG, Conlon M, Cooper-DeHoff R, Volkers P, Zellig P, J Am Coll Cardiol 1998 32 1228 1237 10.1016/S0735-1097(98)00423-9 9809930 (Pubitemid 28522378)
14. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, et al. Jama 2003 290 2805 2816 10.1001/jama.290.21.2805 14657064 (Pubitemid 37509488)
15. Predictors of adverse outcome among patients with hypertension and coronary artery disease. Pepine CJ, Kowey PR, Kupfer S, Kolloch RE, Benetos A, Mancia G, Coca A, Cooper-DeHoff RM, Handberg E, Gaxiola E, et al. J Am Coll Cardiol 2006 47 547 551 10.1016/j.jacc.2005.09.031 16458134 (Pubitemid 43170842)
16. Characteristics of contemporary patients with hypertension and coronary artery disease. Cooper-DeHoff RM, Handberg EM, Cohen J, Kowey P, Messerli FH, Mancia G, Cangiano JL, Gaxiola E, Garcia-Barreto D, Hewkin AC, Pepine CJ, Clin Cardiol 2004 27 571 576 10.1002/clc.4960271010 15553310 (Pubitemid 39299016)
17. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Bakris GL, Gaxiola E, Messerli FH, Mancia G, Erdine S, Cooper-DeHoff R, Pepine CJ, Hypertension 2004 44 637 642 10.1161/01.HYP. 0000143851.23721.26 15381674 (Pubitemid 39435232)
18. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ, JAMA 2010 304 61 68 10.1001/jama.2010.884 20606150
19. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?Ann. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine CJ, Intern Med 2006 144 884 893 (Pubitemid 46768128)
20. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. D'Agostino RB, Lee ML, Belanger AJ, Cupples LA, Anderson K, Kannel WB, Stat Med 1990 9 1501 1515 10.1002/sim.4780091214 2281238
21. A systematic review of the associations between dose regimens and medication compliance. Claxton AJ, Cramer J, Pierce C, Clin Ther 2001 23 1296 1310 10.1016/S0149-2918(01)80109-0 11558866 (Pubitemid 32804122)
22. The epidemiology of serious adverse drug reactions among the elderly. Atkin PA, Veitch PC, Veitch EM, Ogle SJ, Drugs Aging 1999 14 141 152 10.2165/00002512-199914020-00005 10084366 (Pubitemid 29086114)
23. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Kjekshus JK, Am J Cardiol 1986 57 43F 49F 10.1016/0002-9149(86)90888-X 2871745 (Pubitemid 16054097)
24. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Lancet 2002 360 1903 1913 12493255 (Pubitemid 35472129)
25. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Turnbull F, Lancet 2003 362 1527 1535 14615107 (Pubitemid 37410190)
26. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. Law MR, Morris JK, Wald NJ, BMJ 2009 338 1665 10.1136/bmj.b1665 19454737
27. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, Mureddu G, Pede S, Maggioni AP, Lucci D, Reboldi G, Lancet 2009 374 525 533 10.1016/S0140-6736(09)61340-4 19683638
28. Demystifying optimal dynamic treatment regimes. Moodie EE, Richardson TS, Stephens DA, Biometrics 2007 63 447 455 10.1111/j.1541-0420.2006.00686.x 17688497 (Pubitemid 47222560)
29. Comparison of dynamic treatment regimes via inverse probability weighting. Hernan MA, Lanoy E, Costagliola D, Robins JM, Basic Clin Pharmacol Toxicol 2006 98 237 242 10.1111/j.1742-7843.2006.pto-329.x 16611197
30. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, et al. Circulation 2011 123 18 e209 10.1161/CIR.0b013e3182009701 21160056
31. Variability of blood pressure and the results of screening in the hypertension detection and follow-up program. J Chronic Dis 1978 31 651 667 730822
32. Blood pressure measurement error: its effect on cross-sectional and trend analyses. Bennett S, J Clin Epidemiol 1994 47 293 301 10.1016/0895-4356(94) 90010-8 8138839 (Pubitemid 24109741)
33. Misleading measurements: modeling the effects of blood pressure misclassification in a United States population. Marshall T, Med Decis Making 2006 26 624 632 10.1177/0272989X06295356 17099201 (Pubitemid 44728779)
34. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997 157 2413 2446 9385294
35. Evaluation of response-time data involving transient states-illustration using heart-transplant data. Mantel N, Byar DP, J Am Stat Assoc 1974 69 81 86 10.1080/01621459.1974.10480131